Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Loxo Oncology, Inc. | a17-8614_18k.htm |
Exhibit 16.1
March 21, 2017
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Ladies and Gentlemen:
We have read the statements made by Loxo Oncology, Inc. in its Form 8-K dated March 21, 2017, which we understand will be filed with the Commission, pursuant to Item 4 of Form 8-K. We agree with the statements concerning our Firm in such Form 8-K.
Very truly yours,
/s/ CohnReznick LLP